

Assessment of lipid per-oxidation and endothelial dysfunction in patients of coronary artery disease

Anita Sharma^{1*}, Ashish Sharma²

¹Associate Professor, ²Professor and HOD, Dept. of Biochemistry, ¹Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, ²Geetanjali Medical College, Udaipur, Rajasthan, India

*Corresponding Author: Anita Sharma
Email: dranitasharmabio@gmail.com

Received: 20th July, 2018

Accepted: 3rd October, 2018

Abstract

Aim: To find the difference in the levels of homocysteine and lipid-peroxidation in male and female patients of coronary artery disease.

Materials and Methods: 71 subjects were included in this study over a period of 12 months out of which 12 female patient of CAD, 29 male patient of CAD and 30 were normal healthy subjects as controls. Estimation of plasma malondialdehyde (MDA) was done by colorimetric technique on RA 50 semi-automated chemistry analyzer. The homocysteine level in the plasma was estimated using the Hcy enzymatic assay on SYNCHRON CX5, Automated Chemistry Analyzer of Beckman Coulter Ltd.

Results: We found significant increased levels of Hcy and MDA in male CAD patients than in female CAD patients.

Conclusion: In female CAD patients, decreased levels of Hcy and MDA are indication of low oxidative stress that may be due to female sex hormones.

Keywords: Coronary artery disease (CAD), Homocysteine (Hcy), Lipid-peroxidation, S-adenosylhomocysteine (SAH).

Introduction

Atherosclerotic disease that involves the cerebrovascular, coronary and peripheral system is a major health problem in the adult population worldwide in the developed and developing nations.¹ And of these, the CAD is the leading disease in the industrialized nations and has emerged as a dominant chronic condition in many parts of the world. It is predicted to become the leading cause of disability and death worldwide in the 21st century, and is expected to claim almost 25 million lives annually, thus surpassing infectious disease as the world number one cause of death and disability.² A few emerging risk factors have also been identified such as lipoprotein 'a', homocysteine, prothrombotic factor and pro-inflammatory factor along with the classical risk factors for the development of CAD.³

The combination of homocysteine, homocystine, homocysteine thiolactone, and homocysteine mixed disulfides in the serum is described by the term Homocysteine (tHcy or H (e)). Elevation in the plasma tHcy is multifactorial, i.e. increased dietary intake, heritable enzyme deficiencies and vitamin cofactor deficiencies all play a part (4). An elevation of plasma tHcy >15 μmol/L is usually defined as Hyperhomocysteinemia, and may be caused by genetic defects, nutritional deficiency of folate, vitamin B₆ or Vitamin B₁₂, renal insufficiency, certain drugs, or the physiological factors such as the advancing age, males, menopause.⁵

The exact mechanisms leading to tHcy toxicity are unknown, and it is believed that they are due to its metabolite that adversely affects vascular endothelium and inducing atherosclerosis by several mechanisms such as

1. Auto oxidation of homocysteine
2. By causing endothelial injury
3. Effect on haemostasis

4. Effect on smooth muscle proliferation
5. Oxidative modification of low density lipoprotein
6. Formation of Hcy-thiolactone.

Hcy auto-oxidation and thiolactone formation promote the production of free radicals which are well known initiators of lipid peroxidation in cells. Aldehydes such as thiobarbituric acid reacting substances (TBARS) are widely accepted general marker for free radical production, of which, the one measured most commonly is malondialdehyde (MDA).⁶ The objective of the present study was to find the difference in the levels of Hcy and MDA in male and female patients of coronary artery disease.

Materials and Methods

The present study was conducted on 71 subjects over a period of 12 months in the Department of Biochemistry and Cardiology of Himalayan Institute of Medical Sciences, Swami Rama Nagar, Doiwala, Dehradun after getting approval from ethical committee of Himalayan Institute of Medical Sciences and informed consent were taken from all the subjects prior to the study. The patients were from the intensive care unit of Cardiology Department at HIMS. The study included 12 female cases and 29 male cases of CAD. The study also included 30 normal age matched healthy adults (20 males and 10 females), who served as controls.

Study Group: The study included 12 female cases and 29 male cases of CAD according to the standard diagnostic criteria.⁷

Control Group: Included 30 normal age matched healthy adults (20 males and 10 females), without clinical evidence of coronary artery disease and with normal ECG constituted the control group.

Exclusion Criteria: Subjects with renal failure, hepatic dysfunction, pregnancy, hypothyroidism, and those taking Methotrexate, Carbamazepine or phenytoin were excluded from the study.

Collection of Samples: All samples were collected in the morning after 12hrs of overnight fasting. 2 ml of blood was drawn by venepuncture from the antecubital vein in an EDTA vacutainer for estimation of plasma MDA and homocysteine. Estimation of plasma malondialdehyde was done by colorimetric technique on RA 50 semi-automated chemistry analyzer. MDA was measured by method of Ceconi, Cargoni, Pasini et al. 100µl of serum was diluted with 500µl of distilled water. The samples were kept in boiling water bath for 15 minutes. To the diluted sample 1 ml of trichloric acid and thiobarbituric acid reagent was added. The reaction mixture was cooled and centrifuged. The optical density of pink coloured supernatant was taken on 535 nm on colorimeter. The concentration of MDA is directly proportional to the optical density. Estimation of plasma homocysteine was done on SYNCHRON CX5, Automated Chemistry Analyzer of Beckman Coulter Ltd. Homocysteine level in the plasma was estimated using the

Hcy enzymatic assay as marketed by Diazyme. In Diazyme enzyme assay oxidized Hcy is first reduced to free Hcy, which then react with S- adenosylmethionine to form free methionine and S- adenosyl homocysteine (SAH). SAH is further assessed by coupled enzyme reaction including SAH hydrolase, adenosine deaminase and glutamate dehydrogenase. The result of all the parameters undertaken were tabulated and statistically analysed by students "t test" from which p value were obtained.

Results

Table 1 shows the mean and standard error in control subjects. The mean level of Hcy were significantly increased in male control subjects as compared to female control subjects but there is no significant difference between the mean level of MDA in female and male control subjects. Table 2 represents the mean level of MDA and Hcy in CAD patients. Higher levels of plasma Hcy and MDA were obtained in male than female cases of coronary artery disease; this difference was statistically insignificant for both the parameters (MDA & Hcy).

Table 1: Hcy and MDA in males and females subject of control group

Parameters	Status	N	Mean± SD	p-value
Hcy µmol/L	Control Female	10	8.66 ±0.98	p<0.001
	Control Male	20	15.84 ±2.02	
MDA µmol/L	Control Female	10	0.60 ±0.04	p=0.20
	Control Male	20	0.53 ± 0.03	

P<0.05 considered as statistically significant

Table 2: The mean levels of Hcy and MDA in female and male subjects with MI

Parameters	Status	N	Mean± SD	p-value
Hcy µmol/L	Control Female	12	28.89 ±1.27	p<0.001
	Control Male	29	34.64 ±2.33	
MDA µmol/L	Control Female	12	1.43 ±0.09	p=0.03
	Control Male	29	1.51 ± 0.10	

P<0.05 considered as statistically significant

Discussion

In the present study, we found significant increased levels of Hcy in male as compared to female in both control and CAD patients. Our study findings for Hcy level is in agreement with Falloni et al.⁸ Modi et al⁹ and Zogte et al¹⁰ in their study observed insignificant increase in Hcy in male subjects as compared to female subjects. The present study indicates that hyperhomocysteinemia is present to a greater extent in male gender and it is possible that this may be related to sex hormones.¹¹ Low levels of homocysteine in

females may be due to their exercise habit and day to day physical activity.¹²

In addition, it was also observed in our studies that plasma MDA level in male CAD patients (1.51±1.97 µmol / L) was higher than female CAD patients (1.433±0.224 µmol / L), none of whom had previous history of MI. This finding is found to be in agreement with the observations of Nielsen, Mikkelsen, Andersen et al who also found higher values of MDA in male subjects having CAD as compared to similar female subjects.¹³ Estrogen has protective effect on lipoprotein metabolism, vascular functions and

endothelial cell lining. It can protect atherosclerosis by reducing oxidative stress and lowering total plasma cholesterol.¹⁴ In addition to vascular and myocardial effects, estrogen also possesses antioxidant property. All estrogen has phenolic group in their structure that causes scavenging of oxygen free radicals. Estrogen can induce antioxidant enzyme expression by stimulating antioxidant defence system.¹⁵ High protein contents in diet, alcohol intake and smoking habits in males may be the cause of high levels of Hcy and MDA in male subjects.

Oxidative stress may play a role in several diseases including atherosclerosis, diabetes mellitus and hypertension and any gender differences associated with oxidative stress could have implications in the mechanisms for these cardiovascular diseases. Pre-menopausal females have lower level of oxidative stress as compared to men this could be due to the anti-oxidant properties of estrogen.¹⁶ Generally, females were more concerned about body shape, eating and body shape and BMI may also play a role in developing oxidative stress and estrogen may not be the only reason for the differences between males and females.

Conclusion

Higher levels of Hcy and MDA were obtained in male cases than in female's cases, indicating protective effect of female sex hormones for hyperhomocysteinemia and oxidative stress in coronary artery disease.

References

1. Setti KK, Mantri RR. Homocysteine- Emerging evidences as an independent risk factor for CAD. *Cardiol Today* 1999;3:122-129.
2. Gaziano JM. General consideration of cardiovascular disease: Global burden of cardiovascular disease. In: Zipes DP, Lippman P and Braunwald E, editors. *Heart disease: A text book of cardiovascular medicine*. 6th ed. Boston: Elsevier Saunders Publishers; 2001. P 1-19.
3. Hackam DG, Anand SS. Emergency Risk Factors for Atherosclerosis Vascular Disease. *J Am Med Assoc* 2003;290:932-940.
4. Scott JM, Weir DG. Folic Acid, Homocysteine and one carbon metabolism: A review of the essential Biochemistry. *J Cardiovasc Risk* 1998;5:223-227.
5. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. *Ann Rev Med* 1998;49:31-62.
6. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia. Vascular injury and arterial thrombosis. *N Engl J Med* 1974;291:537-543.
7. Gersh BJ, Braunwald E, Rutherford JD. Chronic Coronary Artery Disease: In *Heart Disease - Textbook of Cardiovascular Medicine*. 1977 5th ed. Ed. Braunwald, E. and Saunderson, W.B., Philadelphia. 1331-1340.
8. Fallahi E, Sadeghian S, Salarifar M. The relationship between plasma homocysteine levels and early coronary artery disease. *2009;4(1):116-120*.
9. Modi M, Prabhakar S, Majumdar S, Khullar M, Lal V, Das CP. Hyperhomocysteinemia as a risk factor for ischemic stroke: an Indian scenario. *Neurology India* 2005;53(3):297-302.
10. Zongte Z, Debbarma A, Singh TB, Shaini L, Devi SB, Singh WG. Serum Homocysteine levels in Cerebrovascular Accidents. *Indian J Clin Biochem* 2008;23(2):154-157.

11. Arlene L, Arabi N, Kristopher A, Women D, Fadi A, Anjan G et al. Reduction of homocysteine levels in coronary artery disease by low dose folic acid combined with vitamins B6 and B12. *Am J Cardiol* 1999;83:821-825.
12. Hartung GH, Blancq RJ, Lally DA, Krock LP. Estimation of aerobic capacity from submaximal cycle ergometry in women. *Med Sci Sports Exerc* 1995;27:452-457.
13. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. *Clin Chem* 1997;43(7):1209-1214.
14. Kuhl H. Cardiovascular effects and estrogen/gestagen substitution therapy. *Therapeutische Umschau*, 1994;51:748-754.
15. Massafra C, De Felice C, Gioia D & Buonocore G. Variations in erythrocyte antioxidant glutathione peroxidase activity during the menstrual cycle. *Clin Endocrinol* 1998;49:63-67.
16. Kander MC, Cui Y, Liu Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases. *J Cell Mol Med* 2017;21(5):1024-1032.

How to cite this article: Sharma A, Sharma A. Assessment of lipid per-oxidation and endothelial dysfunction in patients of coronary artery disease. *Int J Clin Biochem Res* 2019;6(1):7-9.